Research & Education

Side Effects of Immune Checkpoint Inhibitors

Tuesday, March 21, 2017 at 9:00PM EST - Recording Available

 

 

Julie R. Brahmer, M.D., M.Sc.
Director, Thoracic Oncology Program
Interim Director,
Johns Hopkins Kimmel Cancer Center at Bayview
Associate Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins School of Medicine
Baltimore, MD

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine

Name of Reviewer(s): 

               

Laurie Gaspar, MD –Nothing to Disclose

Name of Planner(s): 

 

Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose

Name of Activity: 

 

Side Effects of Immune Checkpoint Inhibitors

Date of Activity:

 

03/21/2017

Faculty/Speaker(s)Disclosure:

COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’, reviewers, and/or faculty’s et.l. identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Chair: Ramaswamy Govindan, MD

Honoraria with the following: ABBVIE, ARIAD, AZ, BAXALTA, BMS, MERCK and ROCHE.

 

Speaker: Julie Brahmer, MD

Speakers/Advisory Board, Consulting and Research Grant from: Advisory Board/Consulting Agreement: BMS (uncompensated), Celgene, Lilly, Merck; Contracted Research/Grant: BMS, MedImmune/AstraZeneca, Merck.

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

       No

If yes, please list:

With the integration of immunotherapy in the treatment of non-small cell lung cancer, recognition of potential side effects associated with immunotherapy and management of symptoms are essential components of overall care.

After viewing this program, attendees will be able to:

  • Recognize the possible immune related toxicities during or after a patient receives immunotherapy.
  • Identify the possible immune related toxicities during or after a patient receives immunotherapy.
  • Distinguish how to counsel patients about what symptoms to relay to their health care team while receiving immunotherapy.

Following the presentation, there will be ample time for discussion and a question/answer session.  Attendees will be able to submit questions and comments to Dr. Brahmer via internet chat.

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants. 

In order to receive CME credit, attendees must fill out a program evaluation.

Financial/Commercial and Conflicts of Interest Disclosures

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

DOWNLOAD RECORDING

Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.

IASLC Lung Cancer Grand Rounds webinars will continue throughout 2017. The goal is to hold one program monthly. Participants who complete a pre-and post-test along with an evaluation will receive 1 AMA PRA Category 1 CreditTM for each completed webinar.

Use the Time Zone Converter